A Study of HG381 Administered to Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This is a Phase I, first in human, open-label, non-randomized, multicenter study to evaluate
the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary efficacy and
establish a recommended dose of HG381 administered intravenously (IV) alone in subjects with
advanced solid tumors.